Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Jaguar LAA acquires Johnson & Johnson's Afib LAA closure device assets for undisclosed price
Acquisition, cardiovascular, medical devices, equity investment - Read more

Novartis acquires Sironax's blood-brain barrier delivery platform for $125M
Acquisition, neurological, drug delivery, antibody, milestone payments - Read more

Oribiotech secures $120M, 10-year cell therapy manufacturing pact with undisclosed biopharma partner
Manufacturing agreement, cell therapy, automation, milestone payments, commercialization - Read more

Ginkgo Bioworks selected by Novo to build autonomous lab at new Waltham R&D site
Manufacturing agreement, AI/ML, drug discovery, automation, R&D - Read more

Tempest Therapeutics secures exclusive option to license Hebei Senlang Biotechnology's CD7-targeted lentiviral in vivo CAR-T platform
Licensing deal, cell therapy, oncology, autoimmune, gene therapy, milestone payments - Read more

Mighty Therapeutics, POLG Foundation, JAX collaborate to develop preclinical mouse model for POLG mitochondrial disorders and Parkinson's disease
Research collaboration, rare disease, neurological, drug discovery, small molecule - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

Skyhawk Therapeutics' SKY-0515 shows significant Ph1/2 improvement in Huntington's disease patients at 15-month mark
Small molecule, neurological, RNA modulation, Huntington's disease, oral therapy - Read more

Sling Therapeutics raises $123M Series C to advance oral thyroid eye disease treatment
Small molecule, thyroid eye disease, ophthalmology, clinical-stage - Read more

RegCell raises $66M, Series A and AMED grant for T-cell autoimmune reprogramming platform
Autoimmune, cell therapy, T-cell reprogramming, epigenetic platform, clinical-stage - Read more

HexemBio raises $15.5M in total funding, advancing three-generation longevity cell therapy platform
Longevity, cell therapy, synthetic biology, stem cell, preclinical - Read more

Circle Pharma raises $92.5M Series E to advance cyclin D1 inhibitor for breast cancer
Oncology, small molecule, breast cancer, macrocycle, clinical-stage, AI/ML platform - Read more

Mithrl raises $20M Series A to launch AI infrastructure platform for biopharma drug development
AI/ML platform, biopharma, drug discovery, platform technology - Read more

Aitiologic raises €6.4M ($7.4M) Seed, developing tissue-resolved liquid biopsy precision medicine solutions
Liquid biopsy, precision medicine, cell-free DNA, AI/ML platform, preeclampsia, women's health - Read more

Dr. Reddy's Laboratories launches NIVORZ nivolumab biosimilar in India, targeting ₹3,900 crore immuno-oncology market
Biosimilar monoclonal antibody, oncology, competitive, revenue impact - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

BioMarin discontinues Voxzogo (vosoritide) Ph2 development for Noonan syndrome amid shifting treatment landscape
Protein therapy, rare disease, CNP analog, Noonan syndrome, achondroplasia - Read more

Novartis halts (lifonebart) TREM2 stabilizer development after Ph2 failure in amyotrophic lateral sclerosis
Protein therapy, neurological, TREM2 stabilizer, ALS, neurodegeneration - Read more

MaaT Pharma's appeal fails as EMA panel upholds negative opinion on GvHD candidate Xervyteg
Microbiome therapy, graft-versus-host disease, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here